KalVista Pharmaceuticals, Inc. (KALV)
14.91
-0.21
(-1.39%)
USD |
NASDAQ |
Feb 13, 16:00
14.90
-0.01
(-0.07%)
After-Hours: 20:00
KalVista Pharmaceuticals Enterprise Value : 727.07M for Feb. 13, 2026
Enterprise Value Chart
Sep '18
Jan '19
May '19
285.00
270.00
255.00
240.00
Historical Data
Enterprise Value Definition
EV is considered the theoretical purchase ("takeover") price of a business because a purchaser would take on the company's debt, while pocketing the company's cash and gaining a right to all of the company's future earnings.
Enterprise Value Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Enterprise Value Benchmarks
| BioCryst Pharmaceuticals, Inc. | 2.146B |
| Iovance Biotherapeutics, Inc. | 771.90M |
| Plus Therapeutics, Inc. | 21.24M |
| BioStem Technologies, Inc. | 73.47M |
| Protokinetix, Inc. | 3.210M |
Enterprise Value Related Metrics
| Net Income (Quarterly) | -49.48M |
| Revenue (Quarterly) | 13.69M |
| Total Expenses (Quarterly) | 63.17M |
| EPS Diluted (Quarterly) | -0.9183 |
| Gross Profit Margin (Quarterly) | 91.00% |
| Profit Margin (Quarterly) | -361.4% |
| Earnings Yield | -26.91% |
| Normalized Earnings Yield | -26.76 |